Glimepiride 0.5 mg, Voglibose 0.2 mg & Metformin Hydrochloride (SR) 500 mg Tablets – GLIMITERIS TRIO 0.5/0.2/500 Complete Guide
What is GLIMITERIS TRIO 0.5/0.2/500 for?
GLIMITERIS TRIO 0.5/0.2/500, from Steris Healthcare, is a prescription combination containing Glimepiride 0.5 mg, Voglibose 0.2 mg, and Metformin Hydrochloride (SR) 500 mg. It is used for the management of type 2 diabetes mellitus when blood-glucose control is not adequately achieved through lifestyle measures or when combination therapy is considered appropriate by a healthcare professional.
The three ingredients work through complementary mechanisms. Glimepiride stimulates the pancreas to release insulin, metformin SR reduces glucose production by the liver and improves insulin sensitivity, while voglibose delays carbohydrate digestion and helps reduce the rise in blood glucose after meals.
Why This Combination Is Important
Type 2 diabetes may involve insulin resistance, increased glucose production by the liver, insufficient insulin secretion, and elevated post-meal blood glucose. Addressing these different factors can sometimes require more than one antidiabetic mechanism.
GLIMITERIS TRIO 0.5/0.2/500 combines three approaches to glucose management. Metformin supports insulin sensitivity and reduces hepatic glucose production, glimepiride increases insulin secretion, and voglibose helps control post-meal glucose absorption.
This medicine should be used together with a suitable diet, regular physical activity, appropriate weight management, and blood-glucose monitoring as recommended by a healthcare professional.
Key Benefits of GLIMITERIS TRIO 0.5/0.2/500
What are the benefits of this combination?
- Helps control elevated blood glucose in appropriate patients with type 2 diabetes.
- Supports insulin secretion through glimepiride.
- Reduces hepatic glucose production through metformin.
- Improves insulin sensitivity through metformin.
- Helps reduce post-meal glucose spikes through voglibose.
- Provides three complementary mechanisms in one prescribed treatment.
- May support more comprehensive glycemic control when combination therapy is clinically appropriate.
Individual response varies, so treatment targets should be based on the patient's medical condition and healthcare professional's recommendations.
Mechanism of Action
Glimepiride belongs to the sulfonylurea class. It acts on pancreatic beta cells and stimulates insulin release. The increased insulin availability helps glucose move from the bloodstream into tissues.
Metformin Hydrochloride SR primarily reduces glucose production by the liver and improves peripheral insulin sensitivity. The sustained-release formulation is designed to release metformin gradually.
Voglibose is an alpha-glucosidase inhibitor. It delays the breakdown of dietary carbohydrates into absorbable sugars in the intestine, thereby helping reduce the rapid increase in blood glucose following meals.
Together:
Glimepiride → increases insulin secretion.
Metformin SR → decreases hepatic glucose production + improves insulin sensitivity.
Voglibose → slows carbohydrate digestion and helps control post-meal glucose elevation.
Side Effects
Possible side effects can include:
- Nausea
- Diarrhea
- Abdominal discomfort
- Bloating
- Flatulence
- Reduced appetite
- Headache
- Dizziness
- Low blood sugar
Gas, bloating, and abdominal discomfort can occur because voglibose changes carbohydrate digestion, while gastrointestinal effects are also commonly associated with metformin.
Serious Side Effects Of GLIMITERIS TRIO 0.5/0.2/500
Hypoglycemia (low blood sugar) is an important potential adverse effect because glimepiride stimulates insulin release. Symptoms may include sweating, shaking, hunger, dizziness, weakness, rapid heartbeat, confusion, or difficulty concentrating. Severe hypoglycemia can cause seizures or loss of consciousness and requires urgent medical attention.
Metformin is rarely associated with lactic acidosis, particularly in people with significant kidney impairment or certain serious medical conditions. Severe weakness, unusual breathing difficulty, persistent abdominal symptoms, or marked drowsiness should receive prompt medical attention.
Available Substitute For This Combination
There is no single substitute suitable for every patient. Depending on individual requirements, a healthcare professional may consider metformin alone, other sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, insulin, or other antidiabetic combinations.
The choice depends on HbA1c, blood-glucose levels, kidney function, cardiovascular health, body weight, hypoglycemia risk, other medicines, and treatment goals. Do not switch or discontinue GLIMITERIS TRIO 0.5/0.2/500 without medical advice.
Dosage Guidelines For GLIMITERIS TRIO 0.5/0.2/500
Take GLIMITERIS TRIO 0.5/0.2/500 exactly as prescribed by your doctor.
- Follow the prescribed dose and timing.
- Take the medicine with meals if directed.
- Avoid unnecessarily skipping meals because glimepiride may cause hypoglycemia.
- Swallow the sustained-release tablet as instructed; do not crush or chew it unless your product-specific instructions permit this.
- Do not double the next dose after a missed dose unless specifically instructed.
- Monitor blood glucose according to your healthcare professional's recommendations.
- Continue the prescribed diet and exercise program.
The dose may require adjustment depending on glucose control, kidney function, age, diet, and risk of hypoglycemia.
Precautions & Warnings
Tell your healthcare professional before taking this medicine if you have:
- Kidney disease or reduced kidney function
- Liver disease
- A history of recurrent hypoglycemia
- Severe infection or dehydration
- Excessive alcohol consumption
- Irregular meal patterns
- A planned surgery
- A medical imaging procedure involving iodinated contrast
- Pregnancy or plans to become pregnant
- Other medicines that affect blood glucose
Kidney function is particularly important when taking metformin-containing medicines. Patients should also inform their doctor about all prescription medicines, over-the-counter products, and supplements to help identify potential interactions.
Conclusion
GLIMITERIS TRIO 0.5/0.2/500 by Steris Healthcare combines Glimepiride 0.5 mg, Voglibose 0.2 mg, and Metformin Hydrochloride (SR) 500 mg to provide complementary blood-glucose-lowering effects for appropriate patients with type 2 diabetes.
Glimepiride promotes insulin secretion, metformin SR reduces hepatic glucose production and improves insulin sensitivity, while voglibose helps control post-meal glucose rises by slowing carbohydrate digestion.
This combination should be used only under professional medical guidance and alongside appropriate nutrition, physical activity, blood-glucose monitoring, and regular follow-up. Because hypoglycemia and other adverse effects are possible, patients should follow the prescribed dosage carefully and should not alter or discontinue treatment without consulting their healthcare professional.
Comments
Post a Comment